SG11201400120UA - Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide - Google Patents
Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamideInfo
- Publication number
- SG11201400120UA SG11201400120UA SG11201400120UA SG11201400120UA SG11201400120UA SG 11201400120U A SG11201400120U A SG 11201400120UA SG 11201400120U A SG11201400120U A SG 11201400120UA SG 11201400120U A SG11201400120U A SG 11201400120UA SG 11201400120U A SG11201400120U A SG 11201400120UA
- Authority
- SG
- Singapore
- Prior art keywords
- ylcarbonylamino
- dimethylaminomethyl
- benzofuran
- benzamide
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161573585P | 2011-09-08 | 2011-09-08 | |
| FR1102727 | 2011-09-08 | ||
| PCT/FR2012/052004 WO2013034863A1 (en) | 2011-09-08 | 2012-09-07 | Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400120UA true SG11201400120UA (en) | 2014-09-26 |
Family
ID=47830027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400120UA SG11201400120UA (en) | 2011-09-08 | 2012-09-07 | Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
| SG10201505619QA SG10201505619QA (en) | 2011-09-08 | 2012-09-07 | Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505619QA SG10201505619QA (en) | 2011-09-08 | 2012-09-07 | Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8883199B2 (en) |
| EP (1) | EP2753322B1 (en) |
| JP (1) | JP6014142B2 (en) |
| KR (1) | KR20140073521A (en) |
| CN (1) | CN103889409A (en) |
| AR (1) | AR087803A1 (en) |
| AU (2) | AU2012306122A1 (en) |
| CA (1) | CA2847011A1 (en) |
| HK (1) | HK1201150A1 (en) |
| MX (1) | MX2014002663A (en) |
| RU (1) | RU2600793C2 (en) |
| SG (2) | SG11201400120UA (en) |
| TW (1) | TWI544920B (en) |
| UA (1) | UA113634C2 (en) |
| UY (1) | UY34295A (en) |
| WO (1) | WO2013034863A1 (en) |
| ZA (1) | ZA201401710B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542445A (en) | 2003-04-07 | 2008-03-28 | Pharmacyclics Inc | Hydroxamates as therapeutic agents |
| WO2008082856A1 (en) * | 2006-12-26 | 2008-07-10 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| EA201201640A1 (en) * | 2007-01-30 | 2013-09-30 | Фармасайкликс, Инк. | METHODS FOR DETERMINING CANCER STABILITY TO INHIBITORS HISTONEDEISETHYLASE |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| ES2627820T3 (en) | 2011-09-13 | 2017-07-31 | Pharmacyclics, Inc. | Histone deacetylase inhibitor formulations in combination with bendamustine and uses thereof |
| US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
| KR101684854B1 (en) * | 2016-06-13 | 2016-12-09 | 아이오틴 주식회사 | Smart medicine case using guardian message notification function, and medication time notification system comprising the same |
| CN114146181B (en) * | 2021-10-29 | 2022-09-09 | 徐诺药业(南京)有限公司 | Combination containing Pan-HDAC and immune checkpoint inhibitor and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1489078E (en) * | 2002-03-28 | 2010-02-24 | Mitsubishi Tanabe Pharma Corp | Benzofuran derivative |
| AU2003226408B2 (en) * | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| NZ542445A (en) * | 2003-04-07 | 2008-03-28 | Pharmacyclics Inc | Hydroxamates as therapeutic agents |
| CN101163485A (en) * | 2005-04-21 | 2008-04-16 | 阿尔扎公司 | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
-
2012
- 2012-08-28 UY UY0001034295A patent/UY34295A/en not_active Application Discontinuation
- 2012-09-06 TW TW101132604A patent/TWI544920B/en not_active IP Right Cessation
- 2012-09-06 US US13/605,116 patent/US8883199B2/en active Active
- 2012-09-07 JP JP2014529056A patent/JP6014142B2/en active Active
- 2012-09-07 WO PCT/FR2012/052004 patent/WO2013034863A1/en active Application Filing
- 2012-09-07 SG SG11201400120UA patent/SG11201400120UA/en unknown
- 2012-09-07 SG SG10201505619QA patent/SG10201505619QA/en unknown
- 2012-09-07 RU RU2014113399/15A patent/RU2600793C2/en not_active IP Right Cessation
- 2012-09-07 UA UAA201403500A patent/UA113634C2/en unknown
- 2012-09-07 CN CN201280041854.3A patent/CN103889409A/en active Pending
- 2012-09-07 AR ARP120103299A patent/AR087803A1/en unknown
- 2012-09-07 EP EP12769146.7A patent/EP2753322B1/en active Active
- 2012-09-07 CA CA2847011A patent/CA2847011A1/en not_active Abandoned
- 2012-09-07 KR KR1020147009191A patent/KR20140073521A/en active Search and Examination
- 2012-09-07 MX MX2014002663A patent/MX2014002663A/en unknown
- 2012-09-07 AU AU2012306122A patent/AU2012306122A1/en not_active Abandoned
-
2014
- 2014-03-07 ZA ZA2014/01710A patent/ZA201401710B/en unknown
- 2014-10-09 US US14/510,369 patent/US20150024040A1/en not_active Abandoned
- 2014-12-23 HK HK14112851.7A patent/HK1201150A1/en unknown
-
2016
- 2016-04-22 AU AU2016202594A patent/AU2016202594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016202594A1 (en) | 2016-05-19 |
| JP6014142B2 (en) | 2016-10-25 |
| AR087803A1 (en) | 2014-04-16 |
| CN103889409A (en) | 2014-06-25 |
| AU2012306122A1 (en) | 2014-03-13 |
| EP2753322B1 (en) | 2016-08-03 |
| KR20140073521A (en) | 2014-06-16 |
| JP2014526457A (en) | 2014-10-06 |
| US8883199B2 (en) | 2014-11-11 |
| WO2013034863A1 (en) | 2013-03-14 |
| CA2847011A1 (en) | 2013-03-14 |
| ZA201401710B (en) | 2015-01-28 |
| UA113634C2 (en) | 2017-02-27 |
| TWI544920B (en) | 2016-08-11 |
| SG10201505619QA (en) | 2015-08-28 |
| RU2014113399A (en) | 2015-10-20 |
| MX2014002663A (en) | 2014-08-29 |
| HK1201150A1 (en) | 2015-08-28 |
| US20150024040A1 (en) | 2015-01-22 |
| TW201313228A (en) | 2013-04-01 |
| UY34295A (en) | 2013-04-30 |
| NZ622112A (en) | 2016-07-29 |
| US20130064880A1 (en) | 2013-03-14 |
| AU2016202594B2 (en) | 2017-09-14 |
| RU2600793C2 (en) | 2016-10-27 |
| EP2753322A1 (en) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201400120UA (en) | Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
| IL242279A0 (en) | Substituted 3-chloro-n-[3-(pyrimidin-2-ylamino)phenyl]propanamide compounds, and salts thereof | |
| AP3589A (en) | A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes | |
| EP2679592A4 (en) | Novel heterocyclic compound, method for producing intermediate therefor, and use thereof | |
| PT2734499T (en) | Merocyanine derivatives | |
| EP2699091A4 (en) | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds | |
| HK1198535A1 (en) | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4] oxazin-3-amine derivatives 5-(3-)-5--5,6--2h-[1,4]-3- | |
| BR112012016786A2 (en) | Processes for preparing 7-methyl-5- (3-piperazin-1-ylmethyl- [1,2,4] oxadiazol-5-yl) -2- (4-trifluoromethoxybenzyl) -2 | |
| HK1184434A1 (en) | Process for the preparation of substituted 3-(1-amino-2-methylpentane-3- yl)phenyl compounds 3-(1--2--3-) | |
| CO6870039A2 (en) | 3- (biphenyl-3-yl) -4-hydroxy-8-methoxy-1-azaspiro [4.5] dec-3-en-2-one substituted | |
| HK1201060A1 (en) | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal 2-(23-)-1- | |
| BR112013019524A2 (en) | Method for the production of 2,3-butanediol by fermentation | |
| BR112013019525A2 (en) | Method for the production of 2,3-butanediol by fermentation | |
| FI20116030A (en) | 500, COPPEL, TX 75019 | |
| BR112012025490A2 (en) | '' method for the production of 1,5 oebtanodiamine '' | |
| HK1190706A1 (en) | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes hsl - | |
| BR112013018973A2 (en) | Process for the preparation of 1-h-pyrrolidine-2,4-dione derivatives | |
| EP2734499A4 (en) | Merocyanine derivatives | |
| TH1401006705A (en) | Method for preparation 2-(2,3-dimethylphenyl)-1-propanal (2-(2,3-dimethylphenyl)-1-propanal) | |
| DK2785675T3 (en) | 5,5-DIMETHYL-2-PROPYL-HEXAHYDRO-2,4A-METHANONAPHTHALENE-1-ON AS SCENTER | |
| TH118939B (en) | Improved process for the preparation of taxen derivatives. | |
| PL396024A1 (en) | Process for the preparation of 4,2', 4'-trihydroxy-6'-methoxy-3'-prenylo-α, ß-dihydrochalcone | |
| DK2461074T3 (en) | Drivetrain ring for machines | |
| PL390882A1 (en) | Composition, especially for the production of a stable emulsion of natural amber | |
| WO2011148253A3 (en) | Solid dosage forms of antipsychotics |